RCS - Belluscura PLC - The US Centers for Medicare & Medicaid Services

BelluscuraAnnouncement

08/07/2021 07:05

RNS Number : 5211E
  
Belluscura PLC
  
08 July 2021
  
 

Belluscura PLC
("Belluscura" or the "Company" or "Group")
 
The US Centers for Medicare & Medicaid Services
Proposed Broadening of Home Use of Oxygen to Treat Cluster Headaches
The US Centers for Medicare & Medicaid Services (CMS) is proposing changes to two separate, but medically related, National Coverage Determinations (NCDs) relating to home oxygen therapy.
First, CMS proposes to remove its NCD at section 240.2.2 of the Medicare NCD Manual, ending coverage with evidence development, and allow the Medicare Administrative Contractors (MACs) to make coverage determinations regarding the use of home oxygen and oxygen equipment for Cluster Headaches (CH).
CMS also proposes to modify its NCD for Home Use of Oxygen at section 240.2 of the Medicare NCD Manual to expand patient access to oxygen and oxygen equipment in the home, and to permit contractors to cover the use of home oxygen and oxygen equipment in order to treat CH and other acute conditions.
Currently Section 240.2, effective since October 27, 1993 provides for home oxygen therapy only if the patient is in the chronic stable state.  CMS has noted, "We note that since the inception of the Public Health Emergency (PHE) due to the COVID 19 pandemic, CMS has begun to permit health care services to increase the capacity of the American health care system outside the setting of the traditional inpatient hospital, including the treatment of acute illnesses."
CMS is seeking comments on its proposed decisions consistent with the public process established by §1862(l) of the Social Security Act. 
Robert Rauker, Belluscura CEO commented: "If approved, this gives another substantial opportunity for Belluscura, in particular with the launch of its X-PLO2R DX Model in the first half of 2022. Shareholders will be kept fully updated on developments from the CMS."
 
For further information please contact:
 




Belluscura plc


www.belluscura.com




Robert Rauker, Chief Executive Officer


via Walbrook PR




Anthony Dyer, Chief Financial Officer


 




 


 




SPARK Advisory Partners Limited (NOMAD)


Tel: +44 (0)20 3368 3550




Neil Baldwin


 




 


 




Dowgate Capital Limited (Broker)


Tel: +44 (0)20 3903 7715




James Serjeant / Nicholas Chambers


 




 


 




Walbrook PR Ltd (Media & Investor Relations)


Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com




Paul McManus / Sam Allen


Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258




 
 
 
About Belluscura plc (www.belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
 
About RNS Reach announcements
RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.
 
 
 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NRADKOBNPBKDQOK